Loading...

CELC CELCUITY INC Expansion Plans 8-K Filing

CLCT

CLC

CELCUITY INC

(CELC)

2025 8-K

Board Expansion

Stockholder Approvals

Financial Results

Positive Trial Results

Financial Results Report

Board Appointment

FDA Application Submitted

Financial Results Release

Clinical Trial Results

Loan Agreement Update

Quarterly Earnings Report

Equity Offerings

Equity Offerings

Debt-Equity Swaps

Market Expansion

Contract Renewal

Financial Statements

Financial Results

Q3 Financial Results

Q2 Financial Results

Underwriting Agreement

Loan Agreement for Phase 3 ...

Earnings Report

Annual Meeting and Plan Ame...

Loan Agreement Amendment

Earnings Release

Investment Disposal

Earnings Reports

Private Placement

Compensation Program Update

Clinical Trial and Collabor...

Financial Results for Q2 2023

Financial Results

Annual Meeting Approval

Earnings Report

Lease Amendment

Deposit Account with Silico...

External Links:

On October 18, 2025, Celcuity Inc. reported positive topline results from its VIKTORIA-1 clinical trial, showing a median progression-free survival of 9.3 months with a three-drug combination, significantly improving over 2.0 months with traditional treatment. The trial marked several milestones, with the FDA NDA submission planned for the fourth quarter of 2025.

AI Assistant

CELCUITY INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.